Semax: the nootropic peptide, explained
A synthetic peptide from a brain-signaling hormone, developed in Russia and studied for focus and cognition.
TL;DR
- Semax is a synthetic peptide derived from a fragment of ACTH (adrenocorticotropic hormone — the brain's primary stress-signaling molecule).
- Early research, mostly in animals, links it to BDNF (brain-derived neurotrophic factor — a protein that helps brain cells grow and connect).
- Semax is not an FDA-approved drug in the US. FDA removed it from Category 2 on April 22, 2026, and it is not on the 503A bulks list.
What it is
Semax is a short synthetic peptide — just seven amino acids (the building blocks of protein) long. It was developed in Russia in the 1980s and is based on a fragment of ACTH (adrenocorticotropic hormone — the body's stress-signaling molecule made by the brain's pituitary gland). Researchers added a small tail to that fragment to make it more stable in the body. The result is a molecule that acts like a key shaped to fit certain brain receptors. It is not a natural substance and it is not an FDA-approved drug.
How it works
Think of your brain cells as having an inbox for certain chemical messages. Semax appears to open that inbox — early research in animals shows it prompts the brain to produce more BDNF (brain-derived neurotrophic factor, in plain English: a protein that acts like fertilizer for brain cells, helping them grow, connect, and survive). A 2004 study found Semax raised BDNF gene expression in rat brain tissue (Dolotov et al., 2006). Research also links it to activity in dopamine (the motivation chemical) and serotonin (the mood chemical) systems. Most of this data comes from rodents, not humans.
Who asks about it
People come to Semax after reading about nootropics — compounds studied in the context of memory, focus, or brain health. Many have already heard about it in online communities and want a plain-language explanation of what it is, how it differs from common supplements, and whether it is accessible through a medical channel in the United States.
What the research says
The published literature on Semax is real but mostly preclinical — meaning it comes from cell studies and animal models. A key 2004 paper (PMID 14556513) showed Semax stimulated BDNF expression in rat hippocampal and cortical tissue — regions involved in learning and memory (Dolotov et al., 2004). A separate study found it activated dopaminergic and serotonergic systems in rodents. Human clinical trials are limited and mostly Russian-language, which makes peer review difficult for Western scientists. Early research suggests interest; it does not establish what Semax does in healthy adults.
What to know before considering it
Semax is not available as an FDA-approved drug in the US. FDA placed Semax in Category 2 in 2023. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Any access requires a licensed prescriber, a legal pharmacy pathway, and a prescription. Do not source it from unregulated vendors.
The Halftime POV
The Semax science is early and interesting. The US regulatory status is in motion. FDA removed Semax from Category 2 on April 22, 2026. In July 2026, FDA's advisory committee voted to recommend Semax for the 503A bulks list, and FDA has not made a final decision. We are watching it closely, and we will keep explaining the science as clearly as we can.
Related reading:
- What is a peptide?
- Receptor specificity: how targeted peptides work
- Why peptides are still Category 2
- Sleep quality and aging research
FAQ
Q: What is Semax? A: Semax is a synthetic peptide derived from a fragment of ACTH (adrenocorticotropic hormone — the brain's stress-signaling hormone). It was developed in Russia and has been studied in the context of cognition and neuroprotection, primarily in animal models.
Q: How does Semax work? A: Early research suggests Semax influences the expression of BDNF (brain-derived neurotrophic factor — a protein that helps brain cells grow and form connections). It has also been studied for effects on dopamine and serotonin activity in rodents.
Q: Is Semax legal in the US? A: Semax is not an FDA-approved drug in the United States. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
Q: How does Halftime Health decide what to prescribe? A: Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed, and only substances that are legally available through our pharmacy partners.
Disclaimer
Several peptides discussed in this article — including Semax — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Dolotov OV et al., "The heptapeptide SEMAX stimulates BDNF expression in different rat brain structures," Neuroscience Letters (2004)
- Manchenko DM et al., "Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents," Neuroscience and Behavioral Physiology (2006)
Frequently asked questions
What is Semax?
Semax is a synthetic peptide derived from a fragment of ACTH (adrenocorticotropic hormone — the brain's stress-signaling hormone). It was developed in Russia and has been studied in the context of cognition and neuroprotection, primarily in animal models.
How does Semax work?
Early research suggests Semax influences the expression of BDNF (brain-derived neurotrophic factor — a protein that helps brain cells grow and form connections). It has also been studied for effects on dopamine and serotonin activity in rodents.
Is Semax legal in the US?
Semax is not an FDA-approved drug in the United States. FDA removed Semax from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, Semax is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.
How does Halftime Health decide what to prescribe?
Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed, and only substances that are legally available through our pharmacy partners.
Keep reading
Buying peptides online? There is a route with labs first and a licensed physician.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.